Guardant Health Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.2B+60.1% YoYTTM through 30 Jun 2026
Net Income -$453.4MTTM through 30 Jun 2026
Free Cash Flow -$240.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 65.2% |
| EBITDA Margin | -36.5% |
| Operating Margin | -40.2% |
| Net Margin | -38.3% |
Returns
203.5%ROE
-23.7%ROA
Balance Sheet Health
Debt / Equity-6.74x
Current Ratio4.03x
Net Debt$449.5M
Cash & Equivalents$1.1B
Quality Metrics
Altman Z-Score4.77
Piotroski F-Score2 / 9
FCF Margin-20.3%
Rule of 40-5.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $982M
Diluted EPS-$3.51TTMFY2025: $-3.32
Dividend
No dividend
Capital Allocation
R&D Spend$375.8M
Capex Intensity4.7%
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.